HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Enhanced therapeutic effect against liver W256 carcinosarcoma with temperature-sensitive liposomal adriamycin administered into the hepatic artery.

Abstract
The antitumor activity of Adriamycin encapsulated in temperature-sensitive liposomes combined with local hyperthermia (HT) was tested in rats bearing well-developed liver W256 carcinosarcoma tumors. Two h after rats received Adriamycin encapsulated in temperature-sensitive liposomes via either the hepatic artery (i.a.) or the femoral vein (i.v.) or free Adriamycin i.a., liver HT was applied at 42 degrees C for 6 min. In animals treated with liposomal Adriamycin i.a., HT resulted in a 38% reduction in the tumor volume ratio and a 2.2-fold increase in the life span of the animals. In animals treated with liposomal Adriamycin i.v. or free Adriamycin i.a., HT did not alter the tumor volume ratio or life span of the animals. Administration i.a. of liposomal Adriamycin markedly increased the tumor drug levels (4-14-fold), reduced the systemic distribution of the drug, and slowed the drug decrease from both the tumor and liver compared with animals treated i.v.. Liver HT in animals treated with liposomal Adriamycin i.a. further increased tumor drug levels by 1.5-2.6-fold, further slowed the drug decrease from the tumor, and resulted in a dissociation of the parallel decrease of drug and lipid from the tumor. This latter effect was not observed in the other groups. These pharmacological findings combined with the lack of beneficial effect from HT in animals treated with free Adriamycin i.a. or liposomal Adriamycin i.v. suggest that i.a. administration of Adriamycin encapsulated in temperature-sensitive liposomes results in a significant retention of intact liposomes in the tumor vasculature that are able to release the encapsulated drug into the tumor cell compartment upon raising the temperature to the phase transition level.
AuthorsY Zou, M Yamagishi, I Horikoshi, M Ueno, X Gu, R Perez-Soler
JournalCancer research (Cancer Res) Vol. 53 Issue 13 Pg. 3046-51 (Jul 1 1993) ISSN: 0008-5472 [Print] UNITED STATES
PMID8319211 (Publication Type: Journal Article)
Chemical References
  • Drug Carriers
  • Liposomes
  • Doxorubicin
Topics
  • Animals
  • Carcinoma 256, Walker (drug therapy, metabolism)
  • Cell Division (drug effects)
  • Cell Survival (drug effects)
  • Combined Modality Therapy
  • Doxorubicin (administration & dosage, pharmacokinetics)
  • Drug Carriers
  • Hepatic Artery (physiology)
  • Humans
  • Hyperthermia, Induced
  • Injections, Intra-Arterial
  • Injections, Intravenous
  • Liposomes
  • Liver (metabolism)
  • Liver Neoplasms, Experimental (drug therapy, metabolism)
  • Male
  • Myocardium (metabolism)
  • Rats
  • Rats, Wistar
  • Sensitivity and Specificity
  • Temperature
  • Tissue Distribution

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: